Disc Medicine will deliver a full Phase 1b update of DISC-0974 in non-dialysis-dependent chronic kidney disease (NDD-CKD) patients with anemia at ASN Kidney Week in early November. The randomized, placebo-controlled study tested single and multiple ascending doses and captured safety, pharmacokinetics, and pharmacodynamic markers, including hepcidin, iron parameters, and hematologic measures. The abstract reflects previously shared findings; the new data package is reserved for the meeting.
The core news is an imminent first look at the totality of dose cohorts in a nephrology population for an anti-hemojuvelin monoclonal antibody designed to suppress hepcidin and release iron restrictions that blunt erythropoiesis in inflammatory states. In CKD anemia, where treatment has oscillated between ESAs, IV iron, and, more recently, HIF-PH inhibitors with mixed regulatory and safety trajectories, a clean mechanistic read on hepcidin modulation could signal a differentiated route to raising hemoglobin without directly stimulating erythropoietin pathways. While Phase 1b is not powered for efficacy, the breadth of pharmacodynamic data will set the bar for what Disc needs to carry into dose-ranging efficacy work.
Strategically, this is an expansion play for a company rooted in iron homeostasis and red cell biology. The choice to anchor early development in NDD-CKD is pragmatic: it sidesteps the confounding procedural burden of dialysis, aligns with ambulatory sites, and targets a large population where ESA use remains cautious and payer controls are stringent. If DISC-0974 can demonstrate consistent hepcidin suppression, improved transferrin saturation, and a directional hemoglobin signal without additive safety liabilities, DISC positions itself against two entrenched paradigms: ESA-based regimens that face cardiovascular scrutiny and HIF-PH inhibitors that carry benefit-risk nuance and regional variability in adoption. The antibody modality could also simplify dosing logistics relative to oral daily regimens, assuming reasonable intervals and outpatient administration.
For sites and CROs, a hepcidin-targeted program raises operational considerations. Centralized, validated hepcidin assays and timely iron panel turnaround will be critical to interpretability; assay variability has tripped past programs in this space. Protocolized iron management, transfusion criteria, and ESA rescue rules will influence both signal detection and operational complexity. Enrollment should be tractable given the prevalence of NDD-CKD anemia, but stratifying by inflammatory burden and baseline iron repletion will matter for data quality. Vendors supporting biomarker analytics, sample logistics, and real-time data monitoring may find this a fertile test bed for embedding PD-driven decision rules into trial conduct.
What matters next is not just whether DISC-0974 moves iron metrics, but whether those changes translate into a durable hemoglobin lift without creating new risks. Watch for the magnitude and consistency of hepcidin reduction across doses, the dependence of hemoglobin movement on concomitant iron or ESA use, and early safety signals tied to iron mobilization: infection rates, liver enzymes, hypertension, and thromboembolic events. Dose proportionality and PK variability will inform feasible dosing intervals and long-term adherence in the outpatient CKD setting. If the signal is coherent, expect a rapid pivot to a Phase 2 dose-ranging trial with hemoglobin change as primary, stringent rescue rules, and predefined subgroups by inflammation and iron status. If biomarker shifts fail to translate to hemoglobin—or if safety flags emerge—Disc will need to recalibrate around combination strategies or narrower phenotypes of anemia of inflammation. The ASN readout will clarify whether hepcidin suppression is ready to challenge current CKD anemia algorithms or remains a promising mechanism still searching for clinical traction.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
